Latest news with #NortonNeuroscienceInstitute
Forbes
22-07-2025
- Health
- Forbes
Breakthroughs Changing The Diagnosis And Treatment Of Alzheimer's
Jerry Klauer, an Alzheimer's patient who received a recently approved therapy to treat the disease, ... More pictured last year in Florida with his wife Jana, a retired physician. In 2012, Phyllis Barkman Ferrell experienced a profound irony. The longtime veteran of Eli Lilly was leading a team preparing to launch a groundbreaking molecule to treat Alzheimer's when her own father was diagnosed with the disease. He became one of approximately 500,000 people diagnosed in the United States with the disease that year. Globally, over 10 million cases of dementia are diagnosed each year, with Alzheimer's contributing a large portion of the burden. Though Ferrell had rare access to top leaders working in the field, her father's path to a diagnosis was not straightforward, and never actually became clear. He spent a week in the hospital and endured a lumbar puncture and the insertion of a shunt in his brain. A PET scan, which can detect abnormal changes in the brain consistent with Alzheimer's disease, cost $10,000 and was not covered by insurance. When Ferrell asked a resident at the hospital to give her father an amyloid test, the resident responded, 'What's an amyloid test?' Amyloid refers to a protein that misfolds and accumulates pathological deposits in the brains of people with Alzheimer's disease. 'Imagine if I could have given him a blood test to see if he had amyloid,' says Ferrell, 'rather than a lumbar puncture and brain surgery?' In fact, that is exactly what has become available – along with two disease-modifying therapies. The New Alzheimer's Workup Today, if patients present with symptoms of memory loss to their primary care provider, they can be referred to a workup for Alzheimer's at a memory clinic with tools that weren't available even three years ago. 'We just got on base at a game that nobody had ever gotten a hit before,' says Ferrell, who now works with the Davos Alzheimer's Collective, a global public health initiative working to improve patients' access to the new innovations. In the new workup, patients can take a digital cognitive assessment, which compares their performance to a standard database. If the patient has a reasonably high chance of having Alzheimer's based on their presentation, then a blood-based biomarker test can be 'very good' at informing the diagnosis, says Dr. Greg Cooper, chief of adult neurology and director of the Memory Center at Norton Neuroscience Institute in Louisville, Kentucky. Jeff Burns, neurologist who co-directs the Alzheimer's Disease Research Center at the University of Kansas in Kansas City, has seen clinicians in his health system order 600 of the blood tests in 11 weeks since the in-house test became available, a sign of their high demand. 'They're very useful in the right context,' he says, adding that he would like to see their use increase in primary care, since memory clinics are 'overloaded' with patients. In Kansas, for instance, there's only one such clinic in the state. If the blood test is positive, patients can go for an insurance-approved PET scan or spinal fluid testing to determine if they are eligible for the new drugs. If the amyloid diagnosis is confirmed, patients can be prescribed one of two monoclonal antibodies, both FDA-approved in 2023, that can slow disease progression by targeting and removing pathological amyloid deposits in the brain. 'It's the first time we can actually alter the trajectory of disease,' Cooper says. A Patient Story Jerry Klauer, 83, is living proof of this remarkable paradigm shift. Several years ago, his wife Jana, a retired physician, began noticing a troubling change in his memory. He was forgetting dates and plans, though he had been impeccably on time before. He also struggled to recall recent events, and his driving became unsafe. Through a connection at the Alzheimer's Drug Discovery Foundation, Jerry got diagnosed with Alzheimer's after a positive blood-based biomarker test and a PET scan confirmed high amyloid buildup. He then became eligible to join a clinical trial of one of the monoclonal antibodies (which has since been FDA-approved). 'I was very fortunate to get into the program early,' says Jerry, who is a co-founder of the Wall Street boutique investment firm Gerard Klauer Mattison and Company. Though he acknowledges that the drug is not a cure, it reduced his amyloid and improved his symptoms. Before he started the drug, his amyloid had to be in a certain high range to qualify. Now, his amyloid measures in the normal range. 'He's stable,' Jana says. 'If he wasn't doing this, he would be getting worse. Is his memory what it was when he was 30 or 40 years told? No, but he lives his life. It's a wonderful life.' Early Intervention Matters Jerry's Alzheimer's disease was not very advanced when he started the monoclonal antibody. That is when the medicine can be most effective. 'In the past,' says Greg Cooper, 'although wrong, people had a nihilistic approach, saying why should I be in a hurry to get a diagnosis? Now the urgency for a diagnosis is compelling.' A major question the field is seeking to answer is just how early does it pay to get diagnosed? The pathological changes in the brain from Alzheimer's start 15 to 20 years before symptoms begin. Current clinical trials that read out in 2027 are testing whether patients who have confirmed amyloid, but zero cognitive decline, stand to benefit from the monoclonal antibodies. Burns predicts that if a benefit is substantiated, there will be a major paradigm shift in screening for Alzheimer's disease. 'It could be coming quickly if the trials of the new drugs work to reduce risk in this population. And if they do, then we will be in a whole different world. Then everyone over 65 should be screened.' That said, amyloid is not the whole story on preventing or delaying Alzheimer's onset. It's an early feature, but removing amyloid only slows, not stops, the disease. 'The focus now is can we stop or slow tau from accumulating?' Burns explains. Tau is a protein that builds up in dead or dying neurons in Alzheimer's disease, and it spreads through the brain. First the amyloid buildup starts, and appears to accelerate the tau. 'So pulling the amyloid out looks like it slows the tau accumulation, but doesn't stop it,' says Burns. An experimental drug in phase 2 clinical trials uses a new approach to reduce the accumulation of tau. 'The tau comes much later than the amyloid,' explains Donna Wilcock, Director of the Center for Neurodegenerative Disorders at Indiana University School of Medicine. 'Amyloid usually precedes the detection of tangle pathology by maybe 10 years. So we may have a 10-year window of catching that amyloid before it starts downstream tau.' In the last decade, researchers have learned that there is a tipping point at which the tau pathology is self-propagating, and the presence or absence of amyloid doesn't affect the tau – dubbed the 'cataustrophe.' 'It seems as though the earlier we can get these amyloid-lowering therapies into patients,' Wilcock says, 'the better the outcome.' What You Can Do To Lower Risk All the experts interviewed for this article stressed the importance of healthy lifestyle habits, which may prevent up to 45.3% of all dementia cases according to the Lancet Commission. These factors are essential: controlling hypertension, blood sugar, and cholesterol, getting regular exercise and seven to eight hours of quality sleep, having an active social life, and eating a largely plant-based Mediterranean diet. 'Controlling a lot of these factors in the mid-life period has the biggest impact on how they affect your risk for dementia later in life,' says Wilcock. 'Mid-life untreated hypertension greatly increases your risk for dementia later in life.' Her own blood pressure started rising in her 40s, and she pushed her primary care doctor to manage it aggressively, noting that she had to 'self-advocate' to get her doctor to take it seriously. 'Through better brain health and attention to modifiable risk factors, how can we eliminate half of dementia before it ever starts?' asks Greg Cooper. 'And for other half, how can we identify it and successfully intervene before we ever have symptoms? It may sound hyperbolic, but I can at least imagine that day.' Jeff Burns concurs that it's an optimistic time for the field, with a broader array of approaches in development than ever before. As of 2023, there were over 140 drugs in clinical trials for Alzheimer's. For patients like Jerry Klauer, breakthrough science is already a clinical reality. Such encouraging experiences and the rapid pace of advancements over the last few years gives me great hope that one day, this terrible disease itself will be long you to Kira Peikoff for additional research and reporting on this article.
Yahoo
20-04-2025
- Health
- Yahoo
People in Their 90s With a Sharp Memory Eat This One Food Daily
Ever heard of the phrase 'brain food'? Certain foods are packed with nutrients that support brain health both short-term (like when you need to focus on something for a prolonged amount of time) and long-term (helping to protect against cognitive decline and dementia). You might have even heard of the MIND diet, a combination of the Mediterranean diet and DASH diet, that is scientifically shown to help reduce the risk of cognitive decline and dementia. In fact, this way of eating has been shown to reduce the risk of Alzheimer's up to 53% —that's major! While keeping your memory sharp doesn't come down to eating one specific food and can't be controlled through diet completely, a neurologist shared with us one food that many people who have a great memory even in their old age have incorporated into their diets. It's been scientifically linked to support long-term memory when eaten regularly. 🩺SIGN UP for tips to stay healthy & fit with the top moves, clean eats, health trends & more delivered right to your inbox twice a week💊 It bears repeating that no one can control their memory completely through what they eat. Memory loss is complicated and it doesn't just come down to one factor. That said, diet does play a significant role in brain health, including long-term memory. According to a 2024 analysis of 23 different scientific studies that took into account diet and memory of people in old age, researchers found that maintaining a whole foods diet (such as the Mediterranean diet or MIND diet) in old age can lead to significant effects on memory and may play a role in protecting against dementia. Related: 'When considering brain health, whether related to Alzheimer's disease or not, it is best to focus on a broad and well-balanced diet such as the Mediterranean diet or the MIND diet,' saysDr. Greg Cooper, MD, PhD, the chief of adult neurology and the director of the Memory Center at Norton Neuroscience Institute. This means eating lots of vegetables, fruit, whole grains, legumes, fish, herbs and unsaturated fats (found in foods like avocado, nuts and seeds, in addition to fish). If you want to add one food to your diet that is scientifically linked to supporting memory, walnuts is a good one to stock up on. 'Walnuts are a rich source of omega-3 fatty acids as well as antioxidants, both of which are thought to be important for brain health, possibly by reducing oxidative stress and inflammation,' Dr. Cooper says. Related: Scientific research shows that a diet including walnuts is linked to better memory, learning, motor coordination and less anxiety than a diet that doesn't include walnuts. As Dr. Cooper explained, this is because the nutrients in walnuts—specifically omega-3s and antioxidants—help lower inflammation. Lower inflammation in the brain means better overall brain health, including memory! Eating walnuts may benefit short-term memory as well. In one 2025 scientific study, young adults who incorporated walnuts into their breakfast experienced better memory recall six hours later than those who didn't have walnuts as part of their breakfast. (However, it should also be noted that the walnut eaters actually had a worse memory two hours after eating, so the benefit was delayed.) Related: The One Thing a Neurologist Is Begging You to Stop Doing In 2025 How many walnuts do you need to eat regularly to experience the brain-supporting benefits? 'Some studies have shown that eating approximately a handful of walnuts can improve our cognitive function. The MIND diet, a diet specifically designed for brain health, recommends consuming at least five servings of nuts, such as walnuts, per week,' Dr. Cooper explains. While walnuts can certainly be enjoyed as-is, Dr. Cooper says some other ways of incorporating them into your diet include adding them to salads or on top of oatmeal—two meals that have other brain-healthy ingredients. Though there is scientific research showing the connection between walnuts and brain health, it's important to remember that they are not the only brain-healthy food. To best support your brain health, eat a wide variety of nutrient-rich foods, not walnuts only. But for a quick, satiating snack, a handful of walnuts is a great one and an excellent example of brain food. Up Next:Dr. Greg Cooper, MD, PhD, chief of adult neurology and the director of the Memory Center at Norton Neuroscience Institute MIND Diet Associated with Reduced Incidence of Alzheimer's Disease. Alzheimer's & Dementia. 2016 The Effect of Whole-Diet Interventions on Memory and Cognitive Function in Healthy Older Adults — A Systematic in Nutrition. 2024 Maximize memory function with a nutrient-rich diet. Mayo Clinic Beneficial Effects of Walnuts on Cognition and Brain 2020 The impact of a walnut-rich breakfast on cognitive performance and brain activity throughout the day in healthy young adults: a crossover intervention trial. Food & Function. 2025
